Tolerogenic Dendritic Cells for Antigen-Specific Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive regimens for preventing graft-versus-host disease (GvHD) and allograft rejection are associated with significant toxicities and non-selective immune suppression, leading to infections and cancer risks, while conventional therapies for autoimmune diseases and chronic inflammatory conditions are insufficient in inducing long-term tolerance.
Innovation Solution
The development of a method to generate tolerogenic dendritic cells (Tr-DC) and the use of soluble HLA-G to induce regulatory T cells, which selectively target alloreactive T cells and promote antigen-specific tolerance, thereby reducing immune responses and preventing graft rejection and autoimmune disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive drugs are used to prevent GvHD and allograft rejection, then graft survival is improved, but toxicity and risk of infections increase
Solution Approach 1:
The patent uses tolerogenic dendritic cells as intermediary agents that mediate between the graft and the host immune system. These engineered DCs express soluble HLA-G and are pulsed with alloantigens to actively induce regulatory T cells, which then mediate antigen-specific tolerance. This intermediary approach replaces non-selective drug suppression with targeted immunological mediation, reducing toxicity while maintaining graft protection.
Solution Approach 2:
The invention fundamentally changes the immunological parameters of the graft by engineering dendritic cells to express soluble HLA-G and present specific alloantigens. This parameter change shifts the immune response from rejection to tolerance by modifying the antigen-presenting capabilities and co-stimulatory signals of the graft cells, thereby achieving protection without conventional immunosuppressive drugs.
2Reliability
If non-selective immunosuppression is applied to prevent rejection, then graft acceptance is improved, but cancer risk increases
Solution Approach 1:
The patent applies local quality by engineering dendritic cells to present specific alloantigens through soluble HLA-G, creating a localized and specific tolerogenic effect. Rather than systemic immunosuppression that affects all immune functions, the tolerogenic DCs deliver targeted antigen-specific tolerance, preserving the host's ability to mount anti-tumor and anti-infectious immune responses while accepting the graft.
Solution Approach 2:
Tolerogenic dendritic cells serve as intermediaries that deliver antigen-specific tolerance signals without requiring broad immunosuppression. By using these specialized cells as mediators, the system achieves graft acceptance through controlled immunological dialogue rather than blanket suppression, thereby maintaining cancer surveillance capabilities.
3Object-affected harmful factors
If conventional therapies are used for autoimmune diseases, then inflammation is reduced, but long-term tolerance is not achieved
Solution Approach 1:
The patent employs preliminary action by pre-engineering dendritic cells with soluble HLA-G and pulsing them with autoantigens before administration. This preliminary preparation creates a primed tolerogenic state that actively induces regulatory T cells, establishing long-term tolerance mechanisms before the autoimmune response fully develops, rather than merely suppressing inflammation after it occurs.
Solution Approach 2:
Tolerogenic dendritic cells act as intermediaries that deliver sustained antigen-specific tolerance signals to induce durable regulatory T cell populations. This intermediary mechanism creates long-lasting immunological memory for tolerance, overcoming the transient effect of conventional anti-inflammatory therapies and achieving prolonged disease remission.
Data Source
AI summary
The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity.